These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 20564411)

  • 1. Differential impact of high-dose cyclophosphamide, topotecan, and vincristine in clinical subsets of patients with chemoresistant neuroblastoma.
    Kushner BH; Kramer K; Modak S; Qin LX; Cheung NK
    Cancer; 2010 Jun; 116(12):3054-60. PubMed ID: 20564411
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A phase II study of topotecan with vincristine and doxorubicin in children with recurrent/refractory neuroblastoma.
    Garaventa A; Luksch R; Biasotti S; Severi G; Pizzitola MR; Viscardi E; Prete A; Mastrangelo S; Podda M; Haupt R; De Bernardi B
    Cancer; 2003 Dec; 98(11):2488-94. PubMed ID: 14635085
    [TBL] [Abstract][Full Text] [Related]  

  • 3. High-dose cyclophosphamide inhibition of humoral immune response to murine monoclonal antibody 3F8 in neuroblastoma patients: broad implications for immunotherapy.
    Kushner BH; Cheung IY; Kramer K; Modak S; Cheung NK
    Pediatr Blood Cancer; 2007 Apr; 48(4):430-4. PubMed ID: 16421906
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Evaluation of efficacy of treatment for 30 children with neuroblastoma].
    Sun XF; Liu DG; Su YS; Lin TY; Chen XQ; He YJ
    Ai Zheng; 2003 Dec; 22(12):1343-5. PubMed ID: 14693065
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Response to paclitaxel, topotecan, and topotecan-cyclophosphamide in children with untreated disseminated neuroblastoma treated in an upfront phase II investigational window: a pediatric oncology group study.
    Kretschmar CS; Kletzel M; Murray K; Thorner P; Joshi V; Marcus R; Smith EI; London WB; Castleberry R
    J Clin Oncol; 2004 Oct; 22(20):4119-26. PubMed ID: 15483021
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Reduction from seven to five cycles of intensive induction chemotherapy in children with high-risk neuroblastoma.
    Kushner BH; Kramer K; LaQuaglia MP; Modak S; Yataghene K; Cheung NK
    J Clin Oncol; 2004 Dec; 22(24):4888-92. PubMed ID: 15611504
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treatment of relapsed aggressive lymphomas: regimens with and without high-dose therapy and stem cell rescue.
    Hagemeister FB
    Cancer Chemother Pharmacol; 2002 May; 49 Suppl 1():S13-20. PubMed ID: 12042984
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Topotecan by 21-day continuous infusion in children with relapsed or refractory solid tumors: a Children's Oncology Group study.
    Hawkins DS; Bradfield S; Whitlock JA; Krailo M; Franklin J; Blaney SM; Adamson PC; Reaman G
    Pediatr Blood Cancer; 2006 Nov; 47(6):790-4. PubMed ID: 16435380
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Results of induction chemotherapy in children older than 1 year with a stage 4 neuroblastoma treated with the NB 97 French Society of Pediatric Oncology (SFOP) protocol.
    Valteau-Couanet D; Michon J; Boneu A; Rodary C; Perel Y; Bergeron C; Rubie H; Coze C; Plantaz D; Bernard F; Chastagner P; Bouzy J; Hartmann O
    J Clin Oncol; 2005 Jan; 23(3):532-40. PubMed ID: 15659499
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Topotecan and cyclophosphamide in patients with refractory or relapsed Ewing tumors.
    Hunold A; Weddeling N; Paulussen M; Ranft A; Liebscher C; Jürgens H
    Pediatr Blood Cancer; 2006 Nov; 47(6):795-800. PubMed ID: 16411206
    [TBL] [Abstract][Full Text] [Related]  

  • 11. High-dose cyclophosphamide-irinotecan-vincristine for primary refractory neuroblastoma.
    Kushner BH; Kramer K; Modak S; Yataghene K; Cheung NK
    Eur J Cancer; 2011 Jan; 47(1):84-9. PubMed ID: 20934323
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatment of advanced neuroblastoma: feasibility and therapeutic potential of a novel approach combining 131-I-MIBG and multiple drug chemotherapy.
    Mastrangelo S; Tornesello A; Diociaiuti L; Pession A; Prete A; Rufini V; Troncone L; Mastrangelo R
    Br J Cancer; 2001 Feb; 84(4):460-4. PubMed ID: 11207038
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy of topotecan and cyclophosphamide given in a phase II window trial in children with newly diagnosed metastatic rhabdomyosarcoma: a Children's Oncology Group study.
    Walterhouse DO; Lyden ER; Breitfeld PP; Qualman SJ; Wharam MD; Meyer WH
    J Clin Oncol; 2004 Apr; 22(8):1398-403. PubMed ID: 15007087
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Neuroblastoma in adolescents and adults: the Memorial Sloan-Kettering experience.
    Kushner BH; Kramer K; LaQuaglia MP; Modak S; Cheung NK
    Med Pediatr Oncol; 2003 Dec; 41(6):508-15. PubMed ID: 14595707
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Neuroblastoma.
    Meir HM; Balawi I; Nayel H; Yousef MK; Badawood S; Al-Mobarak M
    Saudi Med J; 2001 Aug; 22(8):674-80. PubMed ID: 11573111
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase II trial of topotecan administered as 72-hour continuous infusion in children with refractory solid tumors: a collaborative Pediatric Branch, National Cancer Institute, and Children's Cancer Group Study.
    Blaney SM; Needle MN; Gillespie A; Sato JK; Reaman GH; Berg SL; Adamson PC; Krailo MD; Bleyer WA; Poplack DG; Balis FM
    Clin Cancer Res; 1998 Feb; 4(2):357-60. PubMed ID: 9516923
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Disseminated neuroblastoma in children older than one year at diagnosis: comparable results with three consecutive high-dose protocols adopted by the Italian Co-Operative Group for Neuroblastoma.
    De Bernardi B; Nicolas B; Boni L; Indolfi P; Carli M; Cordero Di Montezemolo L; Donfrancesco A; Pession A; Provenzi M; di Cataldo A; Rizzo A; Tonini GP; Dallorso S; Conte M; Gambini C; Garaventa A; Bonetti F; Zanazzo A; D'Angelo P; Bruzzi P;
    J Clin Oncol; 2003 Apr; 21(8):1592-601. PubMed ID: 12697885
    [TBL] [Abstract][Full Text] [Related]  

  • 18. High-dose topotecan, melphalan, and cyclophosphamide (TMC) with stem cell support: a new regimen for the treatment of advanced ovarian cancer.
    Donato ML; Gershenson DM; Wharton JT; Ippoliti CM; Aleman AS; Bodurka-Bevers D; Bevers MW; Burke TW; Levenback CF; Wolf JK; Freedman RS; Bast RC; Gajewski JL; Champlin RE
    Gynecol Oncol; 2001 Sep; 82(3):420-6. PubMed ID: 11520135
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase II study of topotecan in combination with dexamethasone, asparaginase, and vincristine in pediatric patients with acute lymphoblastic leukemia in first relapse.
    Hijiya N; Stewart CF; Zhou Y; Campana D; Coustan-Smith E; Rivera GK; Relling MV; Pui CH; Gajjar A
    Cancer; 2008 May; 112(9):1983-91. PubMed ID: 18318429
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Salvage chemotherapy regimens with arsenic trioxide for relapsed or refractory neuroblastoma: a promising approach.
    Liu X; Peng X; Yang S; Liu H; Zhang S; Wang J; Ma Y; Wu Y; Wang Z; Weng W; Li Y
    BMC Cancer; 2024 Sep; 24(1):1140. PubMed ID: 39266997
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.